TSH Biopharm Corporation Limited Stock price

Equities

8432

TW0008432006

Pharmaceuticals

End-of-day quote Taipei Exchange 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
58.3 TWD +3.37% Intraday chart for TSH Biopharm Corporation Limited +5.23% +15.90%
Sales 2022 464M 14.52M Sales 2023 811M 25.35M Capitalization 1.93B 60.38M
Net income 2022 61M 1.91M Net income 2023 62M 1.94M EV / Sales 2022 2.38 x
Net cash position 2022 722M 22.58M Net cash position 2023 765M 23.91M EV / Sales 2023 1.44 x
P/E ratio 2022
29.5 x
P/E ratio 2023
31.2 x
Employees 76
Yield 2022
3.36%
Yield 2023
2.54%
Free-Float 35.47%
More Fundamentals * Assessed data
Dynamic Chart
TSH Biopharm Corporation Limited Announces Directorate Changes on April 1, 2024 CI
TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024 CI
TSH Biopharm Corporation Limited agreed to acquire an unknown stake in TOP Pharm. Medicalware Company Limited from Gu An Engineering Consultants Co., Ltd., Kao Tuan International Consulting Co., Ltd., ANIMATO INTERNATIONAL COMPANY, Shen Feng Co., Ltd. and others for TWD 257.1 million. CI
TSH Biopharm Corporation Limited agreed to acquire 51% stake in TOP Biological Technology Company Limited from Shen Feng Co., Ltd., Gu An Engineering Consultants Co., Ltd., Kao Tuan International Consulting Co., Ltd. ANIMATO INTERNATIONAL COMPANY and others for TWD 44.3 million. CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TSH Biopharm Corporation Limited Announces the Change of Financial Officer, Effective on January 1, 2024 CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Tsh Biopharm Corporation Limited Announces the Change of Audit Committee Members CI
Tsh Biopharm Corporation Limited Announces Dividend for the Year 2022, Payable on July 14, 2023 CI
TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
TSH Biopharm Corporation Limited Announces Board Appointments CI
More news
1 day+3.37%
1 week+5.23%
Current month-8.33%
1 month-9.33%
3 months+15.67%
6 months+27.85%
Current year+15.90%
More quotes
1 week
55.10
Extreme 55.1
59.50
1 month
53.70
Extreme 53.7
65.80
Current year
49.10
Extreme 49.1
66.70
1 year
44.15
Extreme 44.15
66.70
3 years
38.80
Extreme 38.8
66.70
5 years
38.80
Extreme 38.8
82.50
10 years
34.95
Extreme 34.95
114.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 10-08-31
Chief Administrative Officer - 10-08-31
Members of the board TitleAgeSince
Director/Board Member - -
Chairman 72 -
Corporate Officer/Principal - -
More insiders
Date Price Change Volume
24-03-27 58.3 +3.37% 259,882
24-03-26 56.4 -2.08% 263,374
24-03-25 57.6 +3.78% 110,044
24-03-22 55.5 +0.91% 53,640
24-03-21 55 -0.72% 74,468

End-of-day quote Taipei Exchange, March 26, 2024

More quotes
Tsh biopham corporation ltd. is a Taiwan-based company principally engaged in the manufacturing and distribution of medical preparations. The Company primarily provides medicines for cardiovascular, including Amtrel, Rytmonorm, Licodin, Isormol and ISOPTIN SR; medicines for intestines and stomach, including MOPRIDE, Catilon, Gastro-Timelet and Ribarin, and medicines for central nervous, including Aleviatin, Lonine and Lacoxa SR. The Company distributes its products mainly in domestic markets.
More about the company
  1. Stock
  2. Equities
  3. Stock TSH Biopharm Corporation Limited - Taipei Exchange